Biocept's Lung Cancer Liquid Biopsy Test

Biocept has launched a lung cancer liquid biopsy test. The test uses proprietary technology  to detect RET oncogene fusions from a simple blood draw. Genetic alterations in the RET and ROS1 genes were identified in patients with non-small cell lung cancer that have unique and pathologic features that may facilitate identification and enrichment strategies, the company said. The test comes after Biocept launched a blood-based test to detect the ROS1 biomarker in 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.